Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

NCT05107856 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT05107856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05107856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
March 22, 2022
Completion date
January 19, 2024
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, b-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, chronic myelomonocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, small lymphocytic lymphoma